BRIGHTGENE
BrightGene Bio-Medical Technology Co., Ltd.
Trademark Registered: 2021-08-31
Trademark Application Details
NEW APPLICATION - ASSIGNED TO EXAMINER
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79278137 |
| Registration Number | 6465606 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Law Office Assigned | L20 |
| Employee Name | RINKER, ANTHONY MICHAE |
Timeline
| 2019-10-28 | Application Filed |
| 2020-02-10 | Location: TMEG LAW OFFICE 102 |
| 2020-02-10 | Status: Live/Pending |
| 2020-02-10 | Transaction Date |
| 2021-08-31 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  BrightGene Bio-Medical Technology Co., Ltd. |
| Address | Building C25, No.218 Xinghu Street, BioBay, Suzhou Industrial Park,; Suzhou CN |
| Legal Entity Type | Limited Liability Company |
| Legal Entity State | CN |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Injectable solutions for medical purposes; prepared Chinese medicine; chemico-pharmaceutical preparations; medicinal preparations for the mouth in the form of tablets or compressed tablets; medicines for human purposes; biochemical drug; pharmaceutical preparations; chemical preparations for medical purposes; drugs for medical purposes; active pharmaceutical ingredients |
| GS0051 | Injectable solutions for medical purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; prepared Chinese medicine for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; chemical pharmaceutical preparations for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; medicinal preparations for the mouth in the form of tablets or compressed tablets for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; medicines for human purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; biochemical medical drug for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; pharmaceutical preparations for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; chemical preparations for medical purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; drugs for medical purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; active pharmaceutical ingredients for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2020-02-06 | 1 REPR M: |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2020-02-10 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2020-02-10 | 3 DOCK D:Assigned to Examiner |
| APPLICATION FILING RECEIPT MAILED | 2020-02-14 | 4 MAFR O:Outgoing Correspondence |
| NON-FINAL ACTION WRITTEN | 2020-02-18 | 5 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2020-02-19 | 6 RFCR E:E-Mail |
| NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | 2020-03-10 | 7 RFWR P: |
| NON-FINAL ACTION WRITTEN | 2020-03-11 | 8 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2020-03-12 | 9 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2020-03-26 | 10 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2020-03-27 | 11 RFCS P: |
| REFUSAL PROCESSED BY IB | 2020-04-17 | 12 RFNT P: |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2020-09-17 | 13 COAR I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2020-09-17 | 14 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2020-09-17 | 15 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2020-09-17 | 16 TCCA I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2020-09-17 | 17 CHAN I:Incoming Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2020-09-17 | 18 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-09-17 | 19 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-09-18 | 20 TEME I:Incoming Correspondence |
| SUSPENSION LETTER WRITTEN | 2020-10-20 | 21 CNSL R:Renewal |
| LETTER OF SUSPENSION E-MAILED | 2020-10-20 | 22 GNSL S: |
| NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 2020-10-20 | 23 GNS3 O:Outgoing Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2021-05-10 | 24 CNSA O:Outgoing Correspondence |
| ASSIGNED TO LIE | 2021-05-10 | 25 ALIE A:Allowance for Publication |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2021-05-26 | 26 NONP E:E-Mail |
| NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | 2021-05-26 | 27 OP2R P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2021-05-26 | 28 OPNS P: |
| NOTIFICATION PROCESSED BY IB | 2021-06-13 | 29 GPNX P: |
| PUBLISHED FOR OPPOSITION | 2021-06-15 | 30 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2021-06-15 | 31 NPUB E:E-Mail |
| NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2021-07-07 | 32 OPNR P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2021-07-07 | 33 OPNS P: |
| NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | 2021-07-24 | 34 OPNX P: |
| REGISTERED-PRINCIPAL REGISTER | 2021-08-31 | 35 R.PR A:Allowance for Publication |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2021-11-30 | 36 FICR P: |
| FINAL DISPOSITION PROCESSED | 2022-02-07 | 37 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2022-02-07 | 38 FICS P: |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2022-02-27 | 39 FINO P: |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 BRIGHTGENE 85901429 not registered Dead/Abandoned |
BrightGene Bio-Medical Technology CO., Ltd 2013-04-11 |
 BRIGHTGENE 79278137 not registered Live/Pending |
BrightGene Bio-Medical Technology Co., Ltd. 2019-10-28 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 